NASDAQ:SVRA Savara (SVRA) Stock Price, News & Analysis → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free SVRA Stock Alerts $4.72 -0.11 (-2.28%) (As of 05/16/2024 ET) Add Compare Share Share Today's Range$4.71▼$4.8450-Day Range$4.24▼$5.5952-Week Range$2.16▼$5.70Volume457,623 shsAverage Volume862,136 shsMarket Capitalization$652.26 millionP/E RatioN/ADividend YieldN/APrice Target$9.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Savara alerts: Email Address Savara MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside86.4% Upside$8.80 Price TargetShort InterestBearish6.37% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.01Based on 20 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.38) to ($0.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.44 out of 5 starsMedical Sector695th out of 929 stocksPharmaceutical Preparations Industry321st out of 433 stocks 3.5 Analyst's Opinion Consensus RatingSavara has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSavara has only been the subject of 4 research reports in the past 90 days.Read more about Savara's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.37% of the float of Savara has been sold short.Short Interest Ratio / Days to CoverSavara has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Savara has recently increased by 28.36%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSavara does not currently pay a dividend.Dividend GrowthSavara does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SVRA. Previous Next 1.7 News and Social Media Coverage News SentimentSavara has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Savara this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for SVRA on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Savara to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Savara insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.58% of the stock of Savara is held by insiders.Percentage Held by Institutions87.93% of the stock of Savara is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Savara's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Savara are expected to grow in the coming year, from ($0.38) to ($0.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Savara is -12.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Savara is -12.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSavara has a P/B Ratio of 5.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Savara's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Oxford Club348 million Americans lives to END as we know it?348 million American lives are about to change FOREVER.... Because thanks to one shocking A.I. development I'm revealing for the first time today...To see my free research, simply click here now. About Savara Stock (NASDAQ:SVRA)Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.Read More SVRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SVRA Stock News HeadlinesMay 16 at 4:05 PM | businesswire.comSavara Announces New Employment Inducement GrantMay 16 at 1:24 AM | americanbankingnews.comQ2 2024 EPS Estimates for Savara Inc (NASDAQ:SVRA) Decreased by AnalystMay 15 at 6:18 AM | americanbankingnews.comHC Wainwright Weighs in on Savara Inc's FY2028 Earnings (NASDAQ:SVRA)May 15 at 3:38 AM | americanbankingnews.comSavara (NASDAQ:SVRA) Receives "Buy" Rating from HC WainwrightMay 12, 2024 | americanbankingnews.comSavara (NASDAQ:SVRA) Shares Gap Down to $5.07May 10, 2024 | investorplace.comSVRA Stock Earnings: Savara Misses EPS for Q1 2024May 9, 2024 | businesswire.comSavara Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 8, 2024 | americanbankingnews.comSavara (NASDAQ:SVRA) Rating Reiterated by JMP SecuritiesMay 7, 2024 | businesswire.comSavara to Present at the Citizens JMP Life Sciences ConferenceMay 7, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Savara (SVRA)May 3, 2024 | markets.businessinsider.comOptimistic Buy Rating on Savara Amid Anticipated IMPALA-2 Trial SuccessMay 2, 2024 | msn.comFormer state minister late Vishnu Savara's son Hemant is BJP's Palghar candidateApril 25, 2024 | finance.yahoo.comSavara Inc. (SVRA) Stock Price, News, Quote & History - Yahoo FinanceApril 20, 2024 | seekingalpha.comFYBR, BCRX and SABR are among after hour moversApril 11, 2024 | markets.businessinsider.comOptimistic Buy Rating for Savara Based on Molgramostim’s Market Potential and Study OutcomesMarch 22, 2024 | businesswire.comSavara Announces New Employment Inducement GrantMarch 13, 2024 | msn.comSavara Inc. Reports Increased Expenses, Anticipates Positive Data from IMPALA-2 TrialMarch 11, 2024 | msn.comFDA lifts partial hold on Nurix Phase 1 study for NX-2127March 11, 2024 | markets.businessinsider.comBuy Rating Affirmed: Anticipating IMPALA-2 Trial Success and aPAP Treatment Breakthrough with MolgramostimMarch 10, 2024 | finance.yahoo.comSVRA Jul 2024 7.500 callMarch 8, 2024 | markets.businessinsider.comOptimistic Buy Rating for Savara on Molgramostim’s Market Potential and Strong FinancialsMarch 7, 2024 | msn.comSVRA Stock Earnings: Savara Beats EPS for Q4 2023March 7, 2024 | finance.yahoo.comSavara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business UpdateMarch 6, 2024 | usatoday.comBest penny stocks of March 2024March 6, 2024 | finance.yahoo.comSavara to Present at the Barclays 26th Annual Global Healthcare ConferenceSee More Headlines Receive SVRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Savara and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today5/16/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SVRA Previous SymbolAMEX:ANX CUSIPN/A CIK1160308 Webwww.savarapharma.com Phone512-614-1848Fax858-552-0876EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$8.80 High Stock Price Target$16.00 Low Stock Price Target$6.00 Potential Upside/Downside+96.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,700,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-51.95% Return on Assets-40.45% Debt Debt-to-Equity Ratio0.22 Current Ratio14.90 Quick Ratio14.90 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.88 per share Price / Book5.36Miscellaneous Outstanding Shares138,190,000Free Float131,860,000Market Cap$652.26 million OptionableOptionable Beta0.73 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesRobert N. Neville (Age 51)Chairman of the Board, Chief Executive Officer Taneli Jouhikainen (Age 51)President, Chief Operating Officer David L. Lowrance (Age 50)Chief Financial Officer Nevan C. Elam (Age 49)Independent Director Richard J. Hawkins (Age 68)Independent Director Joseph S. McCracken Ph.D. (Age 64)Independent Director Matthew Pauls J.D. (Age 46)Independent Director Yuri Pikover (Age 56)Independent Director More ExecutivesKey CompetitorsSilence TherapeuticsNASDAQ:SLNZymeworksNYSE:ZYMELyell ImmunopharmaNASDAQ:LYELMineralys TherapeuticsNASDAQ:MLYSPharming GroupNASDAQ:PHARView All CompetitorsInsiders & InstitutionsBain Capital Life Sciences Investors LLCBought 332,706 shares on 5/16/2024Ownership: 10.540%Janus Henderson Group PLCBought 746,407 shares on 5/16/2024Ownership: 1.855%AWM Investment Company Inc.Bought 100,000 shares on 5/16/2024Ownership: 0.072%California State Teachers Retirement SystemBought 61,117 shares on 5/16/2024Ownership: 0.055%Price T Rowe Associates Inc. MDBought 4,625 shares on 5/15/2024Ownership: 0.024%View All Insider TransactionsView All Institutional Transactions SVRA Stock Analysis - Frequently Asked Questions Should I buy or sell Savara stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Savara in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SVRA shares. View SVRA analyst ratings or view top-rated stocks. What is Savara's stock price target for 2024? 5 Wall Street analysts have issued 12-month target prices for Savara's shares. Their SVRA share price targets range from $6.00 to $16.00. On average, they expect the company's stock price to reach $8.80 in the next year. This suggests a possible upside of 86.4% from the stock's current price. View analysts price targets for SVRA or view top-rated stocks among Wall Street analysts. How have SVRA shares performed in 2024? Savara's stock was trading at $4.70 at the start of the year. Since then, SVRA shares have increased by 0.4% and is now trading at $4.72. View the best growth stocks for 2024 here. When is Savara's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our SVRA earnings forecast. How were Savara's earnings last quarter? Savara Inc (NASDAQ:SVRA) issued its earnings results on Thursday, March, 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.02. What other stocks do shareholders of Savara own? Based on aggregate information from My MarketBeat watchlists, some companies that other Savara investors own include BioLineRx (BLRX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Geron (GERN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Verastem (VSTM), Agile Therapeutics (AGRX) and Corbus Pharmaceuticals (CRBP). Who are Savara's major shareholders? Savara's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Bain Capital Life Sciences Investors LLC (10.54%), Jennison Associates LLC (6.40%), Vanguard Group Inc. (4.39%), Janus Henderson Group PLC (1.86%), Swiss National Bank (0.11%) and AWM Investment Company Inc. (0.07%). Insiders that own company stock include Badrul A Chowdhury, David A Ramsay, David L Lowrance, Matthew Pauls, Nevan C Elam, Raymond Dennis Pratt and Rick Yang. View institutional ownership trends. How do I buy shares of Savara? Shares of SVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SVRA) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the MarketsObama’s Forever Term [exposed]Porter & CompanyThe 1,000X Crypto PlaybookTrue Market InsidersCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm PressWhy Is Gold On a MASSIVE rally? Huge AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBiden Nomination CANCELED?The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Savara Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
